The current treatment of rheumatoid arthritis (RA) remains limited by severe drug-associated side effects and poor suppression of bone erosion. Herein, we report the development of biomimetic nanoparticles (CEC NPs) that co-deliver celecoxib (CXB) and the lysine-specific demethylase 1 (LSD1) inhibitor CC-90011 via M2 macrophage-derived exosomes (M2 Exos), thereby integrating targeted delivery with innovative multi-mechanistic therapeutic strategies. The M2 Exos enable innate homing to inflamed synovium and osteoclast-rich lesions, while ensuring efficient intracellular delivery. CEC NPs combined repolarize macrophages from the M1 to M2 phenotype, suppress fibroblast-like synoviocyte activation, and critically inhibit bone erosion by blocking the LSD1–NFATc1 signaling pathway in the osteoclast. Collectively, these effects result in potent anti-inflammatory and osteoprotective outcomes. Notably, we identified CC-90011 as a previously unrecognized anti-erosive agent to directly suppress bone erosion in RA treatment. In a collagen-induced arthritis (CIA) model, CEC NPs markedly outperform monotherapies, with pronounced reduction in joint swelling, cartilage degradation, and bone erosion, without systemic toxicity. This work introduces an M2 Exo-based dual-drug delivery system as a versatile strategy for multi-mechanistic modulation of inflammation and bone destruction, offering a promising paradigm that could be extended to other inflammatory and autoimmune bone disorders.
Objectives: The YAP/TAZ pathway is implicated in both obesity and breast cancer (BRCA), but the specific effector genes common to both diseases are unknown. We aimed to identify these shared YAP/TAZ effectors. Methods: We integrated transcriptomic data from BRCA (TCGA, GSE42568) and obesity (GSE25401, GSE151839) datasets. YAP/TAZ-related genes were identified through differential expression analysis, weighted gene co-expression network analysis (WGCNA), and machine learning algorithms. The tumor immune microenvironment was profiled using xCell, ESTIMATE, IPS and TIDE algorithms. The prognostic value was assessed in an independent cohort (GSE25065). Experimental validation was performed using clinical specimens via RT-qPCR. Results: F2R and MXRA5 were identified as core YAP/TAZ-effector genes associated with obesity and BRCA. F2R was upregulated in obese adipose tissue, and both genes exhibited transcriptional dysregulation in BRCA cohorts, though not all differences reached statistical significance between tumor and adjacent normal tissues. Comprehensive immune profiling showed that high expression of F2R/MXRA5 was associated with an immunosuppressive microenvironment, exhibiting reduced infiltration of dendritic cells and macrophages, elevated TIDE scores, and decreased tumor purity. Critically, high expression of either gene predicted significantly poorer overall survival in patients with triple-negative breast cancer (TNBC). Furthermore, computational analysis revealed a positive correlation between F2R/MXRA5 expression and predicted resistance to the HDAC inhibitor Vorinostat, suggesting a potential association with epigenetic therapy resistance. Conclusion: F2R and MXRA5 are novel biomarkers linking obesity to BRCA immunosuppression and poor outcomes, offering potential for risk stratification and combination therapy.